Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of salvianolic acid A in independent-medicine or multiple-medicine-combined nephrotic syndrome treatment

A technology of nephrotic syndrome and salvianolic acid, applied in drug combinations, medical preparations containing active ingredients, pharmaceutical formulas, etc., to reduce the severity of kidney damage, reduce hormone resistance, and overcome side effects

Active Publication Date: 2016-06-22
SUZHOU LEINA PHARMA RES DEV
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] At present, there are no reports of salvianolic acid A treating nephrotic syndrome and inhibiting glomerular podocyte lesions at home and abroad. Therefore, salvianolic acid A is introduced into nephrotic syndrome (single or multi-drug combination therapy) The research has great practical significance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of salvianolic acid A in independent-medicine or multiple-medicine-combined nephrotic syndrome treatment
  • Application of salvianolic acid A in independent-medicine or multiple-medicine-combined nephrotic syndrome treatment
  • Application of salvianolic acid A in independent-medicine or multiple-medicine-combined nephrotic syndrome treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] The preparation of embodiment 1 salvianolic acid A

[0049] 300 grams of salvianolic acid salt was diluted with water to a concentration of 1.0% (calculated as salvia magnesium acetate), adjusted to pH 6.0 with trisodium citrate, converted for 4 hours at 125°C and 0.15MPa, cooled to room temperature, and adjusted with hydrochloric acid. When the pH reaches 2.0-3.0, the content of salvianolic acid A is determined according to the law; the sample solution is passed through the HPD100 resin column, eluted with water and 25% ethanol solution (discarded), and then eluted with 40% ethanol solution to collect salvianolic acid A, according to the law Determine the content of salvianolic acid A, concentrate under reduced pressure until the concentration of salvianolic acid A is about 15.0 ~ 30.0mg / ml; the concentrated solution is passed through a CG161 resin column, eluted with 20% ethanol solution (discarded), and then washed with 35% ethanol solution Collect salvianolic acid A...

Embodiment 2

[0050] Example 2 The protective effect of salvianolic acid A on doxorubicin-induced nephrotic syndrome in rats

[0051] (1) Method

[0052] 1. Sample batch number and source

[0053] Salvianolic acid A, batch number 20130618 provided by Shandong Target Drug Research Co., Ltd., the preparation method is as in implementation 1.

[0054] Prednisone acetate tablets, batch number 130506, Zhejiang Xianju Pharmaceutical Co., Ltd.

[0055] Sodium chloride injection (0.9%), batch number A130529E1, Liaoning Minkang Pharmaceutical Co., Ltd.

[0056] 5% glucose, lot number B14012305, Shandong Hualu Pharmaceutical Co., Ltd.

[0057] 2. Model establishment and administration

[0058] Get 30 rats, be divided into 6 groups at random, be respectively: normal control group, model control group, positive drug group (prednisone acetate 10mg / kg, 0.5% CMC-Na suspension), salvianolic acid A ( 2.5, 5, 10 mg / kg, iv., in 5% glucose). Except for the normal control group, the rats in the other grou...

Embodiment 3

[0099] Example 3 The effect of salvianolic acid A on the nephropathy induced by puromycin aminonucleoside (PAN)

[0100] (1) Method

[0101] SD rats were taken, and a single tail vein injection of puromycin aminonucleoside (PAN) 15 mg / 100 g induced a rat nephropathy model. After PAN was injected for 7 days, the animals were administered in groups, respectively: normal control group, model control group, prednisone 10mg / kg (suspended with 0.5% CMC-Na, ig.), salvianolic acid A (5, 10mg / kg , dissolved in 5% glucose injection, iv.), salvianolic acid A5mg / kg+prednisone 10mg / kg, administered once a day, for 7 consecutive days, the normal control group and the model control group were given an equal volume of glucose solution. During the experiment, observe the general clinical signs of the animals, weigh the body weight, collect the 24h urine of the rats on the 3rd, 7th, and 14th day, centrifuge at 3000rpm for 15min, remove the sediment, collect the supernatant, and store it in a -...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of traditional Chinese medicine effective components, mainly relates to application of salvianolic acid A in independent-medicine or multiple-medicine-combined nephrotic syndrome treatment, discloses application of salvianolic acid A or medicinal salt of salvianolic acid A in independent-medicine or multiple-medicine-combined nephrotic syndrome treatment, and aims at introducing salvianolic acid A to nephrotic syndrome treatment and treating the hormonal resistance type nephrotic syndrome through an independent medicine or multi-medicine combination. By introducing salvianolic acid A, the curative effect of glucocorticoid is enhanced, salvianolic acid A is beneficial to clinical reasonable application of glucocorticoid, the treatment effectiveness of glucocorticoid is improved, and hormone toxicity and hormone resistance are reduced; meanwhile, the action characteristics and molecular mechanism of salvianolic acid A are made clear, reliable foundation is provided for treating the nephrotic syndrome through salvianolic acid A, new routes are opened up for researching new treatment medicine, and certain foundation is established for development of traditional Chinese medicine of the same type.

Description

technical field [0001] The present invention relates to the use of active ingredients of traditional Chinese medicine, and mainly relates to the application of salvianolic acid A in the treatment of nephrotic syndrome alone or in combination with multiple medicines. Background technique [0002] Chronic kidney disease (CKD) has gradually become a major public health problem in my country, and the mortality rate has increased significantly in recent years. At present, there are about 100-120 million chronic kidney disease patients in my country, and effective prevention and treatment measures are urgently needed. [0003] Nephrotic syndrome (NS) is a common and frequently-occurring disease in nephrology. It is a group of clinical syndromes characterized by massive proteinuria, edema, hyperlipidemia and hypoalbuminemia. One of the important reasons. NS has a long course and complicated condition, how to effectively treat it is a major difficulty in the current treatment of r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61K31/573A61K45/06A61P13/12
CPCA61K31/216A61K31/573A61K45/06A61K2300/00
Inventor 范华英刘珂郎跃武杨明艳
Owner SUZHOU LEINA PHARMA RES DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com